Real-World Studies
Breast cancer escalation trials linked to higher research waste, study finds
Tang et alFrontiers in Oncology

A cross-sectional study analyzing 240 phase 2, 3, and 4 randomized clinical trials of breast cancer therapies registered at ClinicalTrials.gov between 2011 and 2021 revealed that research waste is prevalent, affecting 47.1% (113/240) of trials. Research waste was defined by the presence of at least one of three features: nonpublication, inadequate reporting, or design limitations.
The evaluated cohort encompassed 15 de-escalation studies, 139 escalation studies, and 86 other treatment-optimization studies. Marked heterogeneity in structural characteristics was observed between trial types: de-escalation trials were more commonly non-pharmacological (26.7%), national (86.7%), and non-industry-funded (73.3%), while escalation trials more frequently had palliative intent (71.2%) and double-blind designs (42.4%).
After multivariable adjustment for study design, discontinuation, and other trial characteristics, escalation studies had more than a fourfold higher likelihood of research waste compared to de-escalation trials (odds ratio, 4.337; 95% confidence interval, 1.165–18.567; P = 0.028). Investigators noted that tailored strategies are required to mitigate waste across different clinical trial designs, while acknowledging that the small proportion of de-escalation trials (n = 15) represents an exploratory finding requiring further validation.
Key Takeaways
- Escalation trials demonstrated a significantly increased risk of research waste compared with de-escalation trials (adjusted OR, 4.337; 95% CI, 1.165–18.567; P = 0.028).
- Nearly half of all evaluated phase 2 to 4 breast cancer randomized clinical trials (47.1%; 113/240) met criteria for research waste via nonpublication, inadequate reporting, or design limitations.
- De-escalation trials were predominantly non-industry-funded (73.3%) and national (86.7%), whereas escalation studies were primarily palliative in intent (71.2%) and double-blinded (42.4%).
Read the original sourceFrontiers in Oncology
